Highest-materiality recent filing
Globus Medical shareholders approve 1M share increase to equity plan, re-elect directors
Stockholders approved amendment to 2021 Equity Incentive Plan, increasing authorized shares by 1,000,000 to 12,000,000.
Globus Medical Q1 2026: Net sales $759.9M (+27% YoY); raises FY non-GAAP EPS guidance to $4.70-$4.80
GAAP diluted EPS $0.90 (+66.6% YoY); non-GAAP diluted EPS $1.12 (+64.7% YoY).
Director John A. DeFord resigns from Globus Medical Board effective immediately
John A. DeFord, Ph.D., notified the Board of his resignation on March 23, 2026, effective immediately.
Globus Medical Q4 revenue $826.4M (+25.7% YoY); EPS $1.03 GAAP / $1.28 non-GAAP
Q4 worldwide net sales $826.4M, up 25.7% YoY; base business ex-Nevro up 10.6%.
Globus Medical reports record Q4 sales $823M (+25% YoY); FY2026 guidance $3.18-3.22B
Preliminary Q4 2025 sales ~$823.2M, +25.2% YoY; full year sales ~$2.936B, +16.5% YoY.
Globus Medical Q3 revenue $769M (+23% YoY); raises FY2025 EPS guidance to $3.75-$3.85
Net sales $769.0M, +22.9% YoY; base business (ex-Nevro) $669.8M (+7.0%); Nevro contributed $99.3M.
Globus Medical Q2 net sales $745.3M (+18.4%); GAAP EPS $1.49, non-GAAP $0.86
Net sales $745.3M, up 18.4% YoY (17.6% constant currency); US Spine grew 5.7% as-reported.
Globus Medical CEO Scavilla resigns; Pfeil named CEO; preliminary Q2 sales $745.3M (+18% YoY)
Daniel Scavilla resigned as President and CEO effective July 18, 2025 to pursue another opportunity; no disagreement cited.
Globus Medical stockholders approve equity plan amendment, elect directors at annual meeting
Elected four directors to three-year terms: Paul, Lemaitre, Norwalk, Rhoads.
Globus Medical authorizes $500M share repurchase program
Board authorized up to $500M buyback of Class A common stock.
Globus Medical Q1 revenue down 1.4% to $598.1M; cuts non-GAAP EPS guidance to $3.00-$3.30
GAAP net income $75.5M; GAAP diluted EPS $0.54 vs ($0.05) a year ago.
Globus Medical completes acquisition of Nevro Corp. for $5.85/share cash
Completed acquisition of Nevro on April 3, 2025; each Nevro share received $5.85 in cash.
Globus Medical Q4 sales $657.3M (+6.6% YoY); guides 2025 with Nevro acquisition impact
Q4 net sales $657.3M (+6.6% as-reported, +6.9% constant currency); GAAP EPS $0.19, non-GAAP EPS $0.84.
Globus Medical to acquire Nevro for $5.85/sh in all-cash deal valued at ~$250M
All-cash transaction at $5.85/share; 27% premium to 90-day VWAP of $4.61.
Globus Medical prelim Q4 sales $657M (+6.6% YoY), FY24 $2.52B; guides FY25 rev $2.66-2.69B
Q4 2024 preliminary net sales ~$657M, up 6.6% as-reported vs Q4 2023; FY2024 ~$2.52B, up 60.6%.
Globus Medical Q3 net sales $625.7M (+63% YoY), raises FY24 revenue and EPS guidance
Worldwide net sales $625.7M, up 63.1% YoY, driven by NuVasive addition and higher spine/enabling tech sales.
Globus Medical receives FDA warning letter for ExcelsiusGPS complaint procedures
FDA warning letter cites non-conformities in complaint handling, trending, risk reconciliation, and MDR reporting for the ExcelsiusGPS robotic system.
Globus Medical Q2 revenue surges 115.9% to $629.7M; GAAP net income down 45%
Net sales $629.7M, up 115.9% as-reported; GAAP net income $31.8M, down 45% YoY.
Globus Medical shareholders approve amendment to 2021 Equity Incentive Plan
Plan amendment approved with 244,115,224 votes for, 78,950,353 against; effective June 5, 2024.
Globus Medical Q1 net sales $606.7M (+119% YoY); raises FY2024 guidance
Net sales $606.7M, up 119.3% YoY, driven by NuVasive addition and higher spine/enabling tech volumes.
Globus Medical Q4 net sales $616.5M (+124.6% YoY); non-GAAP EPS $0.60; reaffirms FY2024 guidance
Q4 net sales $616.5M, +124.6% as-reported (+123.8% constant currency); driven by NuVasive merger and organic growth.
Globus Medical promotes Keith Pfeil to COO and CFO effective Feb 1, 2024
Keith Pfeil adds COO role to his CFO responsibilities; effective February 1, 2024.
On February 5, 2024, Globus Medical, Inc. (the “Company”) issued a news release announcing the promotion of Keith Pfeil to Chief Operating Officer and Chief Financial Officer, effective as of February 1, 2024.
Max materiality 0.85 · Median 0.75 · Most common event earnings